Related Experiment Video
Updated: Mar 5, 2026

Detection of Plasmodium Sporozoites in Anopheles Mosquitoes using an Enzyme-linked Immunosorbent Assay
Published on: September 30, 2021
Identification of a novel merozoite surface antigen of Plasmodium vivax, PvMSA180
Fauzi Muh1, Jin-Hee Han1, Myat Htut Nyunt1,2
1Department of Medical Environmental Biology and Tropical Medicine, School of Medicine, Kangwon National University, Chuncheon, Gangwon-do, Republic of Korea.
Background:
Although a number of Plasmodium vivax proteins have been identified, few have been investigated as potential vaccine candidates. This study characterized the Plasmodium vivax merozoite surface antigen 180 (PvMSA180, PVX_094920), a novel P. vivax antigenic protein.
Methods:
The target gene was amplified as four overlapping domains (D1, D2, D3 and D4) to enable expression of the recombinant protein using cell-free and bacterial expression systems. The recombinant PvMSA180 proteins were used in protein microarrays to evaluate the humoral immune response of 72 vivax-infected patients and 24 vivax-naïve individuals. Antibodies produced in mice against the PvMSA180-D1 and -D4 domains were used to assess the subcellular localization of schizont-stage parasites with immunofluorescence assays. A total of 51 pvmsa180 sequences from 12 countries (41 sequences from PlasmoDB and 6 generated in this study) were used to determine the genetic diversity and genealogical relationships with DNAsp and NETWORK software packages, respectively.
Results:
PvMSA180 consists of 1603 amino acids with a predicted molecular mass of 182 kDa, and has a signal peptide at the amino-terminus. A total of 70.8% of patients (51/72) showed a specific antibody response to at least one of the PvMSA180 domains, and 20.8% (15/72) exhibited a robust antibody response to at least three of the domains. These findings suggest that PvMSA180 is targeted by the humoral immune response during natural infection with P. vivax. Immunofluorescence analysis demonstrated that PvMSA180 is localized on the merozoite surface of schizont-stage parasites, and pvmsa180 sequences originating from various geographic regions worldwide showed low genetic diversity. Twenty-two haplotypes were found, and haplotype 6 (Hap_6, 77%) of pvmsa180 was detected in isolates from six countries.
Conclusions:
A novel P. vivax surface protein, PvMSA180, was characterized in this study. Most of P. vivax-infected patients had specific antibodies against particular antigenic domains, indicating that this protein is immunogenic in naturally exposed populations. Genetic analysis of worldwide isolates showed that pvmsa180 is less polymorphic than other well-known candidates and that some haplotypes are common to several countries. However, additional studies with a larger sample size are necessary to evaluate the antibody responses in geographically separated populations, and to identify the function of PvMSA180 during parasite invasion.
Insights
This study characterized Plasmodium vivax merozoite surface antigen 180 (PvMSA180), finding it immunogenic in infected patients. PvMSA180 shows low genetic diversity globally, suggesting potential as a vaccine candidate.
Area of Science:
- Malariology
- Immunology
- Parasitology
Background:
- Few Plasmodium vivax proteins are explored as vaccine candidates.
- Plasmodium vivax merozoite surface antigen 180 (PvMSA180) is a novel antigenic protein.
Purpose of the Study:
- Characterize PvMSA180 (PVX_094920) as a potential Plasmodium vivax vaccine candidate.
- Investigate the humoral immune response against PvMSA180 domains.
- Determine the genetic diversity and subcellular localization of PvMSA180.
Main Methods:
- Amplified PvMSA180 gene into four domains for recombinant protein expression.
- Utilized protein microarrays to assess antibody responses in infected patients and naïve individuals.
- Employed immunofluorescence assays for subcellular localization and sequence analysis for genetic diversity.
Main Results:
- A significant proportion of P. vivax-infected patients (70.8%) showed specific antibody responses to PvMSA180 domains.
- PvMSA180 is localized on the merozoite surface of schizont-stage parasites.
- Worldwide pvmsa180 sequences exhibited low genetic diversity with a common haplotype (Hap_6) found across multiple countries.
Conclusions:
- PvMSA180 is immunogenic and targeted by the humoral immune response during natural P. vivax infection.
- Low genetic diversity and common haplotypes suggest PvMSA180's potential as a cross-geographically effective vaccine candidate.
- Further research is needed to confirm antibody responses in diverse populations and elucidate PvMSA180's function in parasite invasion.

